Leuprolide Acetate Injection Depot, 22.5 mg is now available from Cipla

Cipla Limited and its wholly owned subsidiary Cipla USA Inc., announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration (USFDA).

Leuprolide Acetate Injection Depot 22.5mg has been made available, according to Cipla Limited and its wholly-owned subsidiary Cipla USA Inc. The United States Food and Drug Administration has approved the product (USFDA).

Leuprolide Acetate Injection Depot is a single-dose injection device that carries 22.5 mg of leuprolide acetate for three months of treatment. It is provided as lyophilized microspheres in a single dose vial as part of a kit that also includes an easy-to-use MIXJECT® transfer device and a prefilled syringe with 2mL of 0.8% mannitol solution. The palliative therapy of advanced prostate cancer is advised.

According to Cipla North America's CEO, Leuprolide Acetate Injection Depot's introduction solidifies our organization's commitment to providing patients in the US with high-quality, reasonably priced medical care, Access to effective therapies is essential to achieving our goal of "Caring for Life". This launch fits with our plan to grow in the complicated product market."

The LUPRON DEPOT® 22.5 mg strength, manufactured by Abbvie, shares the same active ingredient, method of administration, dosage form, and strength. For the twelve months ending in September 2022, LUPRON DEPOT® 22.5mg generated US sales of USD 197M, according to IQVIA.

Cipla, a multinational pharmaceutical business founded in 1935, focuses on complicated generics, rapid and sustainable growth, and portfolio diversification in its core markets of India, South Africa, North America, and other important regulated and developing markets.

Contact Us:

BlueWeave Research Blog

Phone No: +1 866 658 6826

Email: info@blueweaveconsulting.com